This invention provides different uses of recombinant super-compound interferons (rSIFN-cos)and its equivalent with changed spatial configuration, high efficacy and lowside effects. Therefore, high dose of rSIFN-co may be used. One characteristic ofrSIFN-co is its ability to inhibit the HBV DNA duplication and secretion of HBsAgand HBeAg in pharmacological studies. The cytotoxic effect ofrSIFN-co is only one-eighth (1/8) of currently clinically available interferons butits anti-viral effect is approximately five to twenty (5-20) times higher, andwhen used in vivo it has a broader spectrum of clinical applications and longer biofeedbackresponse. This invention further provides super-compound interferon or itsequivalent, synthesis of artificial gene with codon preference which codesfor said rSIFN-co and its equivalent, vector comprising said gene and appropriate expressionsystem for expression of said rSIFN-co. Finally this invention provides thesuper-compound interferon (rSIFN-co) and its equivalent, a process to produce sameand uses thereof .
